Stockreport

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Biosciences, Inc.  (AURA) 
PDF Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling [Read more]